Skip to content

Search

First Nations Health and Equity

Aboriginal health is everyone's business. The needs of Aboriginal and Torres Strait Islander families and kids is integrated into all relevant areas of our work. Improving the health and wellbeing of Aboriginal and Torres Strait Islander kids and families is an overarching priority for every team at The Kids.

On the road to recovery

In late 2022, six-year-old Megan Hutton was living the dream of many kids her age as she celebrated being named runner-up champion athlete at her school sports carnival.

Deadly bug in researchers’ sight at The Kids

The Institute has become one of the world’s leading Strep A hubs, with multiple teams working in the Institute’s END RHD Program, headed by Associate Professor Asha Bowen, working to understand how Strep A works and find better ways to prevent and control the diseases it causes.

SToP-ping skin sores in the Kimberley

More than 3,000 skin checks have been undertaken as part of a large clinical trial in WA’s Kimberley region aimed at halving the burden of skin sores in school-aged Aboriginal children.

Translating the Eczema Bathing Study: why context and infection burden matter

Asha Jacinta Bernadette Bowen Walton Ricciardo BA MBBS DCH FRACP PhD GAICD FAHMS OAM MBBS (hon) DCH FACD Head, Healthy Skin and ARF Prevention

Infectious disease outcomes associated with inadequate housing and access to healthy living practices in Australia: a systematic review

Inadequate housing and living conditions underpin significant health and wellbeing inequality in Australia, particularly for Indigenous people. This review aimed to define infectious disease (ID) outcomes used to measure the health impact of inadequate housing in Australia within a research context.

Characterising commensal and pathogenic staphylococcal interactions with neonatal and adult blood

The abundant skin commensal, Staphylococcus epidermidis, is the leading cause of late-onset sepsis (LOS) in preterm infants but rarely causes infections in term infants and adults. Staphylococcal virulence mechanisms and the role of the preterm immune responses in driving these life-threatening infections remain poorly understood.

“You can't heal yourself in that setting and you wouldn't expect other people in this country to”: Yarning about housing and environmental health in remote Aboriginal communities

Remote Aboriginal communities in Australia are located on traditional lands holding deep cultural significance and meaning for residents. However, systemic inequity rooted in colonisation has driven persistent housing and health disparities, with inadequate environmental health conditions within homes and communities a prominent example. 

Clinical decision rules for diagnosis of Streptococcus pyogenes sore throat in Fiji: a prospective diagnostic accuracy study

Acute rheumatic fever is an immune-mediated condition triggered by Streptococcus pyogenes sore throat and possibly skin infection, with a substantial burden in resource-limited settings. Clinical decision rules (CDRs) are commonly used to guide antibiotic treatment of sore throat based on signs and symptoms, but their diagnostic accuracy varies by study and setting. This work aimed to assess the accuracy of multiple CDRs in Fiji to diagnose S. pyogenes sore throat.

Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.